Article Text

Download PDFPDF
Original research article
Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure
  1. Gianluigi Savarese1,
  2. Ulrik Sartipy2,3,
  3. Leif Friberg4,
  4. Ulf Dahlström5,
  5. Lars H Lund1,3
  1. 1 Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
  2. 2 Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
  3. 3 Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden
  4. 4 Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden
  5. 5 Department of Cardiology and Department of Medical and Health Sciences, Linkoping University, Linköping, Sweden
  1. Correspondence to Dr Gianluigi Savarese, Department of Medicine, Cardiology Unit, Karolinska Institutet, 171 76 Stockholm, Sweden; gianluigi.savarese{at}ki.se

Footnotes

  • Contributors GS contributed to the conception and design of the research, analysis and interpretation of data, drafting and revising the manuscript. LHL contributed to the conception and design of the research, drafting and revising the manuscript, obtaining funding and supervising work. US, LF and UD performed a critical revision of the manuscript for important intellectual content.

  • Funding This study was supported in part by grants to LHL’s institution from the Swedish Research Council [grants 2013-23897-104604-23 and 523-2014-2336], the Swedish Heart Lung Foundation [grants 20120321 and 20150557], the Stockholm County Council [grant 20110120].

  • Competing interests GS: none related to this manuscript. Research grant from MSD Italy and Swedish Heart- Lung Foundation. US: none related to this manuscript. US was supported by grants from the Swedish Society of Medicine, Karolinska Institutet Foundations and Funds, the Mats Kleberg Foundation (grant number 2016-00015), the Swedish Heart-Lung Foundation (grant numbers 20160522 and 20160525), the Swedish Heart and Lung Association (grant number E101/16), Regional ALF agreement between Stockholm County Council and Karolinska Institutet (grant number 20160329), Åke Wiberg Foundation (grant number M16-0081) and Magnus Bergvall Foundation (grant number 2016-01396) LF: none related to this manuscript. Research grants and consultancy fees from Bayer, BMS, Pfizer and Sanofi. UD: none related to this manuscript. Research grant to the author’s institution from AstraZeneca and honoraria/consultancies to author’s institution from Novartis and AstraZeneca. LHL: there are no conflicts of interest related to the work submitted. Outside the work submitted, there are the following potential conflicts of interest: research grants to author’s institution, speaker’s and/or consulting fees: AstraZeneca, Novartis, Bayer, Vifor Pharma, Relypsa, Boston Scientific, StJude, Medtronic, HeartWare.

  • Ethics approval Regionala erikprövningsnämnden i Linköping.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors GS contributed to the conception and design of the research, analysis and interpretation of data, drafting and revising the manuscript. LHL contributed to the conception and design of the research, drafting and revising the manuscript, obtaining funding and supervising work. US, LF and UD performed a critical revision of the manuscript for important intellectual content.

  • Funding This study was supported in part by grants to LHL’s institution from the Swedish Research Council [grants 2013-23897-104604-23 and 523-2014-2336], the Swedish Heart Lung Foundation [grants 20120321 and 20150557], the Stockholm County Council [grant 20110120].

  • Competing interests GS: none related to this manuscript. Research grant from MSD Italy and Swedish Heart- Lung Foundation. US: none related to this manuscript. US was supported by grants from the Swedish Society of Medicine, Karolinska Institutet Foundations and Funds, the Mats Kleberg Foundation (grant number 2016-00015), the Swedish Heart-Lung Foundation (grant numbers 20160522 and 20160525), the Swedish Heart and Lung Association (grant number E101/16), Regional ALF agreement between Stockholm County Council and Karolinska Institutet (grant number 20160329), Åke Wiberg Foundation (grant number M16-0081) and Magnus Bergvall Foundation (grant number 2016-01396) LF: none related to this manuscript. Research grants and consultancy fees from Bayer, BMS, Pfizer and Sanofi. UD: none related to this manuscript. Research grant to the author’s institution from AstraZeneca and honoraria/consultancies to author’s institution from Novartis and AstraZeneca. LHL: there are no conflicts of interest related to the work submitted. Outside the work submitted, there are the following potential conflicts of interest: research grants to author’s institution, speaker’s and/or consulting fees: AstraZeneca, Novartis, Bayer, Vifor Pharma, Relypsa, Boston Scientific, StJude, Medtronic, HeartWare.

  • Ethics approval Regionala erikprövningsnämnden i Linköping.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles